CureVac (NASDAQ:CVAC – Get Free Report)’s share price traded up 4.7% during mid-day trading on Thursday . The company traded as high as $4.32 and last traded at $4.26. 356,735 shares traded hands during mid-day trading, a decline of 79% from the average session volume of 1,710,864 shares. The stock had previously closed at $4.07.
CureVac Stock Performance
The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The firm has a market capitalization of $934.70 million, a PE ratio of 7.59 and a beta of 2.50. The company’s fifty day simple moving average is $3.13 and its 200 day simple moving average is $3.15.
Institutional Investors Weigh In On CureVac
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. purchased a new stake in CureVac during the 2nd quarter worth about $8,237,000. Jane Street Group LLC boosted its position in shares of CureVac by 239.0% in the third quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after acquiring an additional 55,867 shares during the period. XTX Topco Ltd purchased a new position in CureVac during the second quarter valued at approximately $108,000. Public Employees Retirement System of Ohio bought a new stake in CureVac during the 3rd quarter worth approximately $91,000. Finally, Barclays PLC purchased a new stake in CureVac in the 3rd quarter worth approximately $67,000. Institutional investors own 17.26% of the company’s stock.
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Featured Stories
- Five stocks we like better than CureVac
- Where Do I Find 52-Week Highs and Lows?
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Investing in Travel Stocks Benefits
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- How to buy stock: A step-by-step guide for beginners
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
